Heron Therapeutics vs Kamada
Kamada reported revenue of $180 million in fiscal 2025, 1.2 times Heron Therapeutics' $155 million in fiscal 2025. Heron Therapeutics' revenue grew 7.4% in its latest year, and Kamada's grew 12.1%. Heron Therapeutics had an operating margin of -1.6%, against 14.5% at Kamada. Free cash flow was −$28 million at Heron Therapeutics and $16 million at Kamada.
Side by side
| Heron Therapeutics | Kamada | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $155M | $180M |
| Revenue growth | 7.4% | 12.1% |
| Revenue growth a year, last 5 years | 11.8% | 6.3% |
| Gross margin | 73.3% | 42.3% |
| Operating margin | −1.6% | 14.5% |
| Net margin | −13.0% | 11.2% |
| Free cash flow | −$28M | $16M |
| Free cash flow margin | −18.0% | 8.7% |
| Return on capital | −7.0% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $12M |
| Change in diluted share count | 9.3% | 0.9% |
| Last close | $0.26 | $7.83 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $1.7 million |
| Piotroski F-score | 4 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Heron TherapeuticsKamada
Operating margin
Percent of revenue
Heron TherapeuticsKamada
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Heron TherapeuticsKamada
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Heron Therapeutics and Kamada pages.